In a recent 13F filing, David Rolfe's Wedgewood Partners revealed it had sold its entire stake in animal health company Zoetis. The filing, which reflects trades made during the second quarter ending June 30, 2026, showed the firm sold all 113.54K shares, a holding previously valued at $13.42M. The position had accounted for roughly 2.77% of the investor's reported portfolio.
Wedgewood confirmed the sale in its second-quarter 2026 client letter. The exit coincided with a challenging period for Zoetis, which reported flat revenue and a 5% decrease in net income for the second quarter. The company cited a "pressured Companion Animal market" and increased competition, leading it to lower its full-year guidance for 2026.